Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 12/20 | 0.39 |
| ▸ | LTB4R2 | Q9NPC1 | 7/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | CPA1 | P15085 | 1/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.35 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.34 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.34 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL839866 | 1.00 | AGTR1 (0.39) | AGTR1LTB4R2MMEACECPA1 | |
| SCHEMBL840237 | 0.91 | AGTR1 (0.40) | AGTR1LTB4R2AGTR2ABCB11GP6 | |
| SCHEMBL840469 | 0.91 | AGTR1 (0.40) | AGTR1LTB4R2AGTR2ABCB11GP6 | |
| SCHEMBL839898 | 0.90 | AGTR1 (0.39) | AGTR1LTB4R2MMEABCB11GP6 | |
| SCHEMBL840148 | 0.90 | AGTR1 (0.39) | AGTR1LTB4R2MMEABCB11GP6 | |
| SCHEMBL839333 | 0.87 | AGTR1 (0.39) | AGTR1LTB4R2MMEAGTR2ABCB11 | |
| SCHEMBL839305 | 0.87 | AGTR1 (0.42) | AGTR1LTB4R2MMEAGTR2ABCB11 | |
| SCHEMBL839083 | 0.85 | AGTR1 (0.45) | AGTR1LTB4R2MMEABCB11GP6 | |
| SCHEMBL839267 | 0.85 | MME (0.43) | AGTR1LTB4R2MMEACE | |
| SCHEMBL839266 | 0.85 | MME (0.43) | AGTR1LTB4R2MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143298-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2012-03-27 | — | — | US | disclosed |